European Commission Drops Boehringer Case And Lauds Itself For Receding Patent Abuse
This article was originally published in The Pink Sheet Daily
Boehringer Ingelheim's settlement with Almirall in an alleged patent abuse case shows that the EU pharmaceutical inquiry had a desired effect, the Commission maintains.
You may also be interested in...
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
The European Court of Justice sides with the European Commission: manipulating the patent and regulatory systems to block competitors gets AZ a slap on the wrist and serves as a warning to others.
Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.